China Universal Asset Management Co. Ltd. Boosts Stake in BioNTech SE (NASDAQ:BNTX)

China Universal Asset Management Co. Ltd. raised its position in shares of BioNTech SE (NASDAQ:BNTX) by 63.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,939 shares of the company’s stock after buying an additional 7,340 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in BioNTech were worth $2,249,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. abrdn plc boosted its position in shares of BioNTech by 334.4% during the third quarter. abrdn plc now owns 225,992 shares of the company’s stock valued at $26,841,000 after buying an additional 173,969 shares during the period. Clear Harbor Asset Management LLC purchased a new position in BioNTech in the third quarter valued at about $210,000. DekaBank Deutsche Girozentrale raised its stake in shares of BioNTech by 12.6% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 481,397 shares of the company’s stock worth $56,886,000 after acquiring an additional 53,800 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in BioNTech by 17.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,931 shares of the company’s stock worth $465,000 after buying an additional 582 shares during the last quarter. Finally, Mount Yale Investment Advisors LLC purchased a new stake in shares of BioNTech during the third quarter worth about $244,000. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of recent research reports. JPMorgan Chase & Co. raised shares of BioNTech from an “underweight” rating to a “neutral” rating and raised their price target for the stock from $91.00 to $125.00 in a research report on Monday, September 16th. Morgan Stanley raised BioNTech from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $93.00 to $145.00 in a report on Tuesday, September 24th. Bank of America raised their target price on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. HSBC raised their price target on shares of BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Finally, Jefferies Financial Group upgraded BioNTech from a “hold” rating to a “buy” rating and boosted their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. Five equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $135.54.

BioNTech Stock Performance

Shares of BNTX stock opened at $113.26 on Tuesday. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49. The company has a market cap of $26.92 billion, a P/E ratio of 226.52 and a beta of 0.24. The firm has a fifty day moving average price of $107.73 and a 200 day moving average price of $95.16.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The company’s quarterly revenue was down 23.3% on a year-over-year basis. During the same period last year, the firm earned ($0.86) EPS. Sell-side analysts predict that BioNTech SE will post -3.04 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.